纳米铋化合物抗流感活性的研究.docxVIP

纳米铋化合物抗流感活性的研究 摘要 流感的流行与爆发已经成为全球的公共卫生难题。近年，每年的季节性流感导致全29万-65万人死亡。现今，抗流感的主要药物为神经氨酸酶抑制剂，但由于病毒易变异的特点，耐药毒株的延就报道也在上升。铋及化合物在生物医药的应用相对成熟，主要用于消化道溃疡的治疗，展示出较好的安全性，然而纳米材料药物还在起步阶段，将铋作为抗病毒药物的研究更近空白。目前本论文主要研究纳米氧化铋的抗流感病毒B的活性。 实验结果表明，制备的纳米氧化铋颗粒分平均粒径约在60-70nm左右，形态较好且粒径合适。血凝实验结果显示冻存病毒原液TCID5010-5.25/100μL。纳米铋对qRT-PCR实验结果表明，纳米氧化铋的加入对PCR结果无显著影响。细胞毒性实验结果显示，在纳米氧化铋颗粒浓度较低（1μg/mL-40μg/mL）时，无论是作用时间长短（24-48小时），细胞活性仍达到80%以上，细胞毒性较低。直接杀伤实验结果表明，纳米氧化铋颗粒可以直接与病毒颗粒发生作用，且在1μg/mL时对病毒的抑制率即可达到98%以上，且在更高浓度下，病毒抑制率不随浓度变化发生显著的改变。病毒暴露前加入纳米颗粒实验结果显示，较高浓度10μg/mL的纳米氧化铋颗粒表现出较好的病毒抑制效果。纳米颗粒、病毒及细胞共处理实验显示纳米颗粒对病毒吸附宿主细胞的过程影响较弱。直接击杀实验的上清液病毒活性实验表明，病毒抑制率较高的实验组上清液仍具有较强的病毒生物学活性。 实验证明，本论文中所制备得到的纳米氧化铋颗粒可以有效抑制流感病毒B的活性，这为流感防治乃至其它病毒感染治疗药物的研发提供了新的思路。 关键词 流感病毒 纳米材料 氧化铋 qRT-PCR 血凝 抗病毒活性 The study on the anti - influenza activity of bismuth nanoparticles Abstract Influenza epidemics have become a global public health challenge. Recent years, seasonal flu has killed between 290,000 and 650,000 people annual year. Currently, the main anti-influenza drugs are neuraminidase inhibitors. However, due to the characteristics of virus mutation, the drug-resistant strains are also on the rise. While, the nanomedicine are still in the initial stage, and the research on bismuth as an antiviral drug is almost blank. At present, this paper mainly studies the anti - influenza virus B activity of nano bismuth oxide. The results showed that the average size of the particle of the prepared bismuth oxide nanoparticles was about 60-70nm, with good morphology and suitable particle size. The hemagglutination test results showed that TCID50 is 10-5.25/100μL. The results of qRT-PCR experiment showed that the addition of bismuth oxide had no significant effect on the PCR results. The results of cytotoxicity experiment showed that when the concentration of nano-bismuth oxide particles was relatively low (1 living g/ ml-40 living g/mL), the cell activity still reached more than 80% regardless of the duration of action (24-48 hours) and the cytotoxicity wa